Literature DB >> 8110956

Treatment of Brazilian kala-azar with a short course of amphocil (amphotericin B cholesterol dispersion).

R Dietze1, E P Milan, J D Berman, M Grogl, A Falqueto, T F Feitosa, K G Luz, F A Suassuna, L A Marinho, G Ksionski.   

Abstract

Amphotericin B is an effective but toxic antileishmanial agent. Lipid-encapsulated amphotericin B should have a high therapeutic index for visceral leishmaniasis because reticuloendothelial cells, the sole site in which Leishmania is found, will phagocytize and concentrate the complex. Amphotericin B cholesterol dispersion (Amphocil; 2 mg/[kg.d] intravenously) was administered to 10 Brazilians with kala-azar for 10 days (cohort 1) and to 10 Brazilians with kala-azar for 7 days (cohort 2). All patients were successfully treated: 19 of the 20 patients were without visible parasites in the bone marrow; the mean time to afebrility was 4.2 days; spleen size regressed by a mean of 79% 2 months after therapy; and no patient had clinical or laboratory abnormalities by the end of 6-12 months of follow-up. Side effects were fever and chills accompanied by respiratory distress, but not nephrotoxicity, in children < 3 years of age.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8110956     DOI: 10.1093/clinids/17.6.981

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  17 in total

Review 1.  Kala-azar--new developments in diagnosis and treatment.

Authors:  P Aggarwal; R Handa; S Singh; J P Wali
Journal:  Indian J Pediatr       Date:  1999 Jan-Feb       Impact factor: 1.967

2.  Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis.

Authors:  V Yardley; S L Croft
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

Review 3.  Leishmania and human immunodeficiency virus coinfection: the first 10 years.

Authors:  J Alvar; C Cañavate; B Gutiérrez-Solar; M Jiménez; F Laguna; R López-Vélez; R Molina; J Moreno
Journal:  Clin Microbiol Rev       Date:  1997-04       Impact factor: 26.132

4.  Short- and long-term efficacy of hexadecylphosphocholine against established Leishmania infantum infection in BALB/c mice.

Authors:  Y Le Fichoux; D Rousseau; B Ferrua; S Ruette; A Lelièvre; D Grousson; J Kubar
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

5.  Miltefosine (Impavido): the first oral treatment against leishmaniasis.

Authors:  H Sindermann; S L Croft; K R Engel; W Bommer; H J Eibl; C Unger; J Engel
Journal:  Med Microbiol Immunol       Date:  2003-09-26       Impact factor: 3.402

6.  Combination therapy using sodium antimony gluconate in stearylamine-bearing liposomes against established and chronic Leishmania donovani infection in BALB/c Mice.

Authors:  Swati Pal; Rajesh Ravindran; Nahid Ali
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

7.  Toxicity and antileishmanial activity of a new stable lipid suspension of amphotericin B.

Authors:  Malika Larabi; Vanessa Yardley; Philippe M Loiseau; Martine Appel; Philippe Legrand; Annette Gulik; Christian Bories; Simon L Croft; Gillian Barratt
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

8.  Activity of a heat-induced reformulation of amphotericin B deoxycholate (fungizone) against Leishmania donovani.

Authors:  C Petit; V Yardley; F Gaboriau; J Bolard; S L Croft
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

Review 9.  Amphotericin-B colloidal dispersion. A review of its use against systemic fungal infections and visceral leishmaniasis.

Authors:  R N Brogden; K L Goa; A J Coukell
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

Review 10.  Control of visceral leishmaniasis in latin america-a systematic review.

Authors:  Gustavo A S Romero; Marleen Boelaert
Journal:  PLoS Negl Trop Dis       Date:  2010-01-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.